Across TCGA pan-cancer cohorts, KRTAP10-9 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated KRTAP10-9 data layer compared with 15 for mass-spec protein.
The strongest signal is observed in adrenocortical carcinoma (ACC), where higher KRTAP10-9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KRTAP10-9 expression acts as an unfavorable survival marker.
ACC and LIHC are the cancer types where KRTAP10-9 Mutation most reproducibly stratifies survival.